Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Trial to Evaluate Safety and to Compare the Immunogenicity of 3 DNA Vaccine Prime Schedules Followed by a NYVAC Vaccine Boost in Healthy, HIV-1 Uninfected Adult Participants

Trial Profile

A Phase 1 Clinical Trial to Evaluate Safety and to Compare the Immunogenicity of 3 DNA Vaccine Prime Schedules Followed by a NYVAC Vaccine Boost in Healthy, HIV-1 Uninfected Adult Participants

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs DNA HIV PT123 (Primary) ; NYVAC-C
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 May 2018 Status changed from recruiting to active, no longer recruiting
    • 12 Jun 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top